Sumitomo Pharma Co., Ltd.

This early-phase study tested a new universal influenza vaccine in 144 healthy adults aged 18 to 40. The goal was to check the vaccine's safety and how well it triggers an immune response. Participants received either the vaccine or a placebo, and researchers monitored for side e…